8-K filing — Perspective Therapeutics, Inc. (CATX)
Filed: 2026-10-08 AccNo: 0001193125-26-417384 Size: 224 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors
SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.
9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.